Humana Tops Q2 Earnings Expectations but Lowers Profit Forecast Amid Medicare Advantage Shifts

Humana HUM reported second-quarter earnings that exceeded Wall Street expectations, largely driven by medical expenses aligning with forecasts. However, the company tweaked its 2026 net profit projection downward, signaling caution despite solid revenue growth.

The health insurer posted quarterly net revenue of $40.87 billion, up 26.2%, slightly beating estimates of $40.61 billion. Adjusted earnings came in at $7.61 per share, compared with analysts' consensus of $7.22, indicating operational strength in the quarter.

Yet, the adjusted net profit forecast was lowered to at least $6.52 per share from the prior minimum projection of $8.36, a notable adjustment that caught some off guard. This downgrade highlights ongoing headwinds even as Humana maintains its annual adjusted profit per share target of at least $9.

The firm reported a medical cost ratio of 91.2%, practically on par with the anticipated 91.19%, showing disciplined cost management across both new and existing members. This metric is crucial given rising medical expenses that have been pressuring the Medicare Advantage sector for years.

Medicare Advantage plans, a key profit engine for health insurers, face a tightening squeeze from persistent medical cost inflation and lower reimbursement rates established by regulators. While many insurers are scaling back or outright exiting less profitable markets, Humana is bucking the trend.

The company has been expanding its footprint in the Medicare Advantage space and reported a hefty 23% jump in individual Medicare Advantage plan memberships in the quarter. It reaffirmed expectations for continued growth in both Medicare and Medicaid enrollment annually.

Market participants have been closely watching insurers' ability to keep costs in check following optimistic outlooks from big names like UnitedHealth. In that context, Humana's earnings beat paired with a profit forecast reduction paints a mixed picture.

Despite the downward revision to net profit, the company's growth in membership underscores a strategic commitment to maintaining its Medicare Advantage market presence at a time when peers are retreating. Whether this aggressive enrollment strategy pays off under cost pressures remains to be seen.

Shares of Humana fell nearly 9% in premarket action reflecting investor concerns over the lowered profit guidance. The stock's reaction may also reflect the broader challenges the Medicare Advantage market still faces, despite some signs of operational resilience in the latest earnings report.